title: Mucus altering agents as adjuncts for nonviral gene transfer to airway epithelium.
abstract: Nonviral vectors have been shown to be a safe and valid alternative to recombinant viruses for gene therapy of cystic fibrosis (CF). Nevertheless, gene transfer efficiency needs to be increased before clinical efficacy is likely in man. One barrier to increased efficacy is normal airway mucus. Using an ex vivo model of sheep tracheal epithelium, we show that this barrier can, in part, be overcome by treatment with the mucolytic agents, Nacystelyn or N-acetylcysteine using either a cationic lipid or a cationic polymer as the gene transfer agent. Further, in vivo application of either Nacystelyn or the anticholinergic glycopyrrolate, both clinically used agents, resulted in increased reporter gene expression in the mouse lung, but no significant correction of the bioelectric defect in CF null mice. These results, whilst unlikely to be sufficient in themselves to achieve clinically relevant gene therapy, may be a further useful step in the attainment of this goal.
authors.affiliation: Department of Gene Therapy, Imperial College at the National Heart and Lung Institute, London, UK.
authors.forename: S
authors.initials: S
authors.lastname: Ferrari
authors.forename: C
authors.initials: C
authors.lastname: Kitson
authors.forename: R
authors.initials: R
authors.lastname: Farley
authors.forename: R
authors.initials: R
authors.lastname: Steel
authors.forename: C
authors.initials: C
authors.lastname: Marriott
authors.forename: D A
authors.initials: DA
authors.lastname: Parkins
authors.forename: M
authors.initials: M
authors.lastname: Scarpa
authors.forename: B
authors.initials: B
authors.lastname: Wainwright
authors.forename: M J
authors.initials: MJ
authors.lastname: Evans
authors.forename: W H
authors.initials: WH
authors.lastname: Colledge
authors.forename: D M
authors.initials: DM
authors.lastname: Geddes
authors.forename: E W
authors.initials: EW
authors.lastname: Alton
mesh_terms: D000111:Acetylcysteine / Q000031:analogs & derivatives / Q000494:pharmacology*; D000818:Animals; D015500:Chloramphenicol O-Acetyltransferase / Q000235:genetics*; D018680:Cholinergic Antagonists / Q000494:pharmacology; D003550:Cystic Fibrosis / Q000628:therapy*; D004305:Dose-Response Relationship, Drug; D005100:Expectorants / Q000494:pharmacology*; D015870:Gene Expression / Q000187:drug effects; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000494:pharmacology; D006024:Glycopyrrolate / Q000008:administration & dosage; D007273:Injections, Intramuscular; D008239:Lysine / Q000031:analogs & derivatives / Q000494:pharmacology*; D051379:Mice; D008807:Mice, Inbred BALB C; D018181:Mice, Inbred CFTR; D023421:Models, Animal; D009297:Nasal Mucosa / Q000378:metabolism; D012756:Sheep; D014132:Trachea / Q000187:drug effects / Q000378:metabolism*
chemical_list: D018680:Cholinergic Antagonists; D005100:Expectorants; C086501:N-acetylcysteine lysinate; D015500:Chloramphenicol O-Acetyltransferase; D008239:Lysine; D006024:Glycopyrrolate; D000111:Acetylcysteine